Arch Chemicals, Inc.

USA As Represented by Secretary of the Navy

Thomas J Palys

Jon R Geiger

Patricia Aileen Turley

John D Nelson, Jr

Diana T Ciccognani

John Daniel Nelson, Jr

Michelle L Rioux

Randal J Schoepp

Kara E Schmid

The present invention is directed to a stable, soluble, antimicrobial composition concentrate comprising pyrithione or a pyrithione complex in an amount of from about 0.5% to about 30 weight percent, a zinc source in an amount of from about 0.1% to about 10%, and an organic amine component in an amount of from about 30% to about 80%, said percents being based upon the total weight of the composition concentrate. The invention is also directed to methods of controlling the growth of free-living microorganisms or biofilms using the antimicrobial composition of the invention, and products made using the antimicrobial composition of the invention.

Pyrithione biocides enhanced by zinc metal ions and organic amines

The present invention is directed to an antimicrobial composition, comprising pyrithione or a pyrithione complex; and a zinc or copper or silver source selected from the group consisting of zinc or copper or silver salts, oxides, hydroxides, sulfates, chlorides, metals, and combinations thereof; wherein the weight ratio of the zinc or copper or silver source to the pyrithione or the pyrithione complex is in the range from about 1:300 to about 50:1, and wherein the antimicrobial composition has an enhanced biocidal effect against a variety of free-living microorganisms or biofilms. Also disclosed is a method of inhibiting the growth of free-living microorganisms or biofilm utilizing the above antimicrobial composition, as well as use of such antimicrobial compositions in various products including fuels, fluids, lubricants, coatings, adhesives, sealants, elastomers, soaps, cosmetics, plastic or woven or non-woven fibers, pharmaceuticals, and as preservatives for the above products.

Pyrithione biocides enhanced by silver, copper, or zinc ions

In this application is described the production of recombinant, chimeric, humanized antibodies specific for both BoNt/A and BoNT/B. The humanized antibodies were converted from a mouse anti-BoNT/A/B Fab fragment into a whole human IgG1 antibody. The antibodies are useful in assays for detecting human exposure to BoNT/A and BoNT/B.

Recombinant chimeric human anti-botulinum antibodies

Growing community of inventors

Cascade, MD, United States of America

Thomas J Palys